Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prothrombin complex concentrates for clinical use.

S Chandra, H G Brummelhuis

    Vox Sanguinis
    |November 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Museum material of Rhipicephalus sanguineus sensu Roberts (1965) collected in 1902-1964 from Australia is identical to R. sanguineus sensu lato tropical lineage at the mitochondrial DNA 12S rRNA level.

    Medical and veterinary entomology·2020
    Same author

    Measurement of the Low-Energy Antideuteron Inelastic Cross Section.

    Physical review letters·2020
    Same author

    Extending the window for thrombolysis for treatment of acute ischaemic stroke during pregnancy: a review.

    BJOG : an international journal of obstetrics and gynaecology·2020
    Same author

    Cardiological society of India document on safety measure during echo evaluation of cardiovascular disease in the time of COVID-19.

    Indian heart journal·2020
    Same author

    Precise quantification of the time course of voluntary activation capacity following Botulinum toxin injections in the biceps brachii muscles of chronic stroke survivors.

    Journal of neuroengineering and rehabilitation·2020
    Same author

    Probing the Effects of Strong Electromagnetic Fields with Charge-Dependent Directed Flow in Pb-Pb Collisions at the LHC.

    Physical review letters·2020
    Same journal

    Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

    Vox sanguinis·2026
    Same journal

    Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

    Vox sanguinis·2026
    Same journal

    In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

    Vox sanguinis·2026
    Same journal

    Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

    Vox sanguinis·2026
    Same journal

    Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

    Vox sanguinis·2026
    Same journal

    Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

    Vox sanguinis·2026
    See all related articles

    Prothrombin complex concentrates carry risks like viral hepatitis and clotting issues. Safer preparation and quality control methods are needed to minimize these adverse events in clinical use.

    Area of Science:

    • Hematology
    • Clinical Pharmacology
    • Biotechnology

    Background:

    • Prothrombin complex concentrates (PCCs) are critical for managing bleeding disorders.
    • Clinical use of PCCs is associated with significant adverse reactions.
    • Factor VIII inhibitors in hemophilia A present unique treatment challenges.

    Purpose of the Study:

    • To review adverse reactions associated with clinical prothrombin complex concentrates.
    • To discuss preparation, quality control, and thrombogenicity of PCCs.
    • To explore PCC use in hemophilia A patients with factor VIII inhibitors.

    Main Methods:

    • Literature review of adverse events and preparation methods.
    • Analysis of quality control measures for PCCs.
    • Discussion of thrombogenicity detection and prevention strategies.

    Related Experiment Videos

    Main Results:

    • Viral hepatitis and thromboembolic complications are frequently observed adverse reactions.
    • Preparation and quality control influence product safety.
    • PCCs are used in hemophilia A patients with factor VIII inhibitors, requiring careful thrombogenicity assessment.

    Conclusions:

    • Enhanced quality control and preparation are essential for safer PCCs.
    • Minimizing thrombogenicity is crucial for reducing adverse events.
    • Further research into safer PCC formulations and administration is warranted.